NYSEAMERICAN:HEB Hemispherx BioPharma (HEB) Stock Price, News & Analysis → Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (From American Alternative) (Ad) Free HEB Stock Alerts $0.43 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.43▼$0.4650-Day Range N/A52-Week Range$1.69▼$14.81Volume157,939 shsAverage Volume102,599 shsMarket Capitalization$1.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsStock AnalysisChartFinancialsSEC Filings Get Hemispherx BioPharma alerts: Email Address Ad American AlternativeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB)Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.Read More HEB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEB Stock News HeadlinesApril 17, 2024 | americanbankingnews.comHemispherx BioPharma (NYSEAMERICAN:HEB) Shares Cross Above 200 Day Moving Average of $0.00January 7, 2024 | cbsnews.comH-E-B hosting hiring fairsApril 25, 2024 | American Alternative (Ad)Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...October 3, 2023 | chron.comH-E-B bets on loyal customers as it expands affordable Joe V’s storesAugust 28, 2023 | chron.comH-E-B enters the film world with a five-part docuseries covering Texas parks and wildlifeJuly 1, 2023 | bizjournals.comH-E-B opens doors to new Georgetown grocery storeJune 27, 2023 | thestreet.comHemispherx's Ampligen Dealt FDA BlowMarch 29, 2023 | marketwatch.comYS Biopharma Down 38%; Reports Favorable Covid-19 Vaccine ResultsApril 25, 2024 | American Alternative (Ad)Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...March 11, 2023 | marketwatch.comFirst Wave BioPharma Shares Rise 9% After Dosing First Patient With AdrulipaseFebruary 26, 2023 | dallasnews.comH-E-B plans to hire 700 for its McKinney storeJanuary 26, 2023 | dallasnews.comH-E-B worker starts petition over grocer’s sick policy after testing positive for COVIDJanuary 12, 2023 | dallasnews.comH-E-B starts its plans for a second Frisco store near Little ElmJanuary 12, 2023 | bizjournals.comH-E-B working on plans for a second Frisco store — this time near Little ElmOctober 29, 2022 | bizjournals.comAre you ready for another H-E-B? Fort Worth location will break ground soonSeptember 23, 2022 | bizjournals.comHere's everything you need to know about H-E-B Frisco, which opens todaySeptember 17, 2022 | thestreet.comEbola Outbreak Puts the Spotlight on 10 Biotech CompaniesAugust 24, 2022 | thestreet.comHemispherx CEO Spills Ampligen Beans to Stock Cheerleader: BioBuzzMay 31, 2022 | news.yahoo.comOrganic Strawberries Tied to a Hepatitis A Outbreak Are Being Recalled Across North AmericaSee More Headlines Receive HEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2019Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:HEB Previous SymbolNYSE:HEB CUSIPN/A CIK946644 Webwww.hemispherx.net Phone+1-407-2718516FaxN/AEmployees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,442,000Free FloatN/AMarket Cap$1.04 million OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Thomas K. Equels (Age 66)Exec. Vice Chairman, CEO & Pres Mr. Adam Pascale (Age 71)Chief Financial Officer Mr. Peter W. Rodino III (Age 68)J.D., Exec. Director of Gov.al Relations, Gen. Counsel & Sec. Mr. Wayne S. Springate (Age 48)Sr. VP of Operations Ms. Ellen LintalChief Accounting OfficerKey Competitors9 Meters BiopharmaNASDAQ:NMTRNovaBay PharmaceuticalsNYSEAMERICAN:NBYEiger BioPharmaceuticalsNASDAQ:EIGRCannLabsOTCMKTS:CANLBiodexa PharmaceuticalsNASDAQ:BDRXView All Competitors HEB Stock Analysis - Frequently Asked Questions How were Hemispherx BioPharma's earnings last quarter? Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) released its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter. When did Hemispherx BioPharma's stock split? Hemispherx BioPharma shares reverse split before market open on Tuesday, June 11th 2019. The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Hemispherx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Biocept (BIOC), Goodrich Petroleum (GDPMQ), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN), Biopharmx (BPMX), CTI BioPharma (CTIC), Ayala Pharmaceuticals (ADXS), Cytori Therapeutics (CYTX) and Frontier Communications (FTR). How do I buy shares of Hemispherx BioPharma? Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:HEB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemispherx BioPharma, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
